Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator-Reference-Cited by-同舟云学术

Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator

Published:2006-08 Issue:4 Volume:16 Page:224-239
ISSN:1096-6374
Container-title:Growth Hormone & IGF Research
language:en
Short-container-title:Growth Hormone & IGF Research

Author:

Juncker-Jensen A.,Lykkesfeldt A.E.,Worm J.,Ralfkiær U.,Espelund U.,Jepsen J.S.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference64 articles.

1. Tamoxifen in the treatment of breast cancer;Osborne;N. Engl. J. Med.,1998

2. RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice;Van de Velde;J. Steroid Biochem. Mol. Biol.,1994

3. Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment;Van de Velde;Ann. N. Y. Acad. Sci.,1995

4. Endocrine-responsive breast cancer and strategies for combating resistance;Ali;Nat. Rev. Cancer,2002

5. Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer;Katzenellenbogen;Breast Cancer Res. Treat.,1997

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IGFBP2 in cancer: Pathological role and clinical significance (Review);Oncology Reports;2020-12-09

2. Overexpression of IGFBP2 mRNA predicts poor survival in patients with glioblastoma;Bioscience Reports;2019-06

3. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark;Growth Hormone & IGF Research;2019-02

4. Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study;Cancer Medicine;2018-05-03

5. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity;Oncotarget;2017-06-27